ChemoMetec AS (OCSE:CHEMM) Payments of Debt: kr0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:CHEMM ChemoMetec AS OCSE:CHEMM
99 GF Score
Price kr410.60
GF Value kr551.60
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ChemoMetec AS Payments of Debt?

ChemoMetec AS OCSE:CHEMM +0.34% 99 Payments of Debt is kr0.0 Mil as of Dec. 2025. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr551.60 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ChemoMetec AS's Payments of Debt for the six months ended in Dec. 2025 was kr0.0 Mil.

ChemoMetec AS's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.0 Mil.

ChemoMetec AS Payments of Debt Related Terms

ChemoMetec AS Payments of Debt Historical Data

* Premium members only.

The historical data trend for ChemoMetec AS's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChemoMetec AS Payments of Debt Chart

ChemoMetec AS Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.01 0.00 -5.40

ChemoMetec AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -5.12 0.00 0.00
OCSE:CHEMM
99GF Score
ChemoMetec AS OCSE:CHEMM
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ChemoMetec AS Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of kr0.0 Mil mean?
ChemoMetec AS (OCSE:CHEMM) has a Payments of Debt of kr0.0 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on ChemoMetec AS and its competitors.
Is ChemoMetec AS's Payments of Debt too high?
ChemoMetec AS's current Payments of Debt is kr0.0 Mil. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Payments of Debt compare to ABT and SYK?
ChemoMetec AS's Payments of Debt of kr0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on ChemoMetec AS and its competitors. ChemoMetec AS's current Payments of Debt is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr551.60, compared to a current price of kr410.60 — trading 25.6% below its estimated fair value. The current Payments of Debt is kr0.0 Mil. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current Payments of Debt is kr0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?

Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued. The current stock price of kr410.60 is trading 25.6% below its estimated GF Value™ of kr551.60. GuruFocus considers ChemoMetec AS to be Modestly Undervalued.

Key valuation signals for OCSE:CHEMM:

  • Payments of Debt: kr0.0 Mil
  • GF Value™: kr551.60 vs. price of kr410.60 (25.6% below fair value)
  • GF Score™: 99/100 with 2 warning signs

No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ChemoMetec AS Business Description

Other Exchanges CHEMMc:UK0DZ0:UKCHY:Germany
Address Gydevang 43, Allerod, DNK, 3450
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score

Get the complete analysis for OCSE:CHEMM

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr410.60
Price
kr551.60
GF Value